NervGen Pharma Corp.
NGEN
$3.57
-$0.15-3.91%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 60.26% | -53.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.54% | -4.18% | |||
| Operating Income | -2.54% | 4.18% | |||
| Income Before Tax | -539.66% | 54.14% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -539.66% | 54.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -539.66% | 54.14% | |||
| EBIT | -2.54% | 4.18% | |||
| EBITDA | -2.54% | 4.19% | |||
| EPS Basic | -537.38% | 54.92% | |||
| Normalized Basic EPS | -536.05% | 54.90% | |||
| EPS Diluted | -537.38% | 54.92% | |||
| Normalized Diluted EPS | -536.05% | 54.90% | |||
| Average Basic Shares Outstanding | 0.47% | 1.68% | |||
| Average Diluted Shares Outstanding | 0.47% | 1.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||